386 related articles for article (PubMed ID: 26842625)
1. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
2. Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.
Fall B; Scott CR; Mauer M; Shankland S; Pippin J; Jefferson JA; Wallace E; Warnock D; Najafian B
PLoS One; 2016; 11(12):e0168346. PubMed ID: 27992580
[TBL] [Abstract][Full Text] [Related]
3. Increased urinary CD80 excretion and podocyturia in Fabry disease.
Trimarchi H; Canzonieri R; Schiel A; Costales-Collaguazo C; Politei J; Stern A; Paulero M; Rengel T; Andrews J; Forrester M; Lombi M; Pomeranz V; Iriarte R; Muryan A; Zotta E; Sanchez-Niño MD; Ortiz A
J Transl Med; 2016 Oct; 14(1):289. PubMed ID: 27733175
[TBL] [Abstract][Full Text] [Related]
4. Podocyturia in Fabry disease.
Pereira EM; Silva AS; Labilloy A; Monte Neto JT; Monte SJ
J Bras Nefrol; 2016 Mar; 38(1):49-53. PubMed ID: 27049364
[TBL] [Abstract][Full Text] [Related]
5. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
6. Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies.
Hayman SR; Calle JC; Jatoi A; Craici IM; Wagner SJ; Weaver AL; Greene EL; Grande JP; Garovic VD
Oncology; 2014; 86(5-6):271-8. PubMed ID: 24902997
[TBL] [Abstract][Full Text] [Related]
7. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes.
Trimarchi H; Canzonieri R; Costales-Collaguazo C; Politei J; Stern A; Paulero M; González-Hoyos I; Schiel A; Rengel T; Forrester M; Lombi F; Pomeranz V; Iriarte R; Muryan A; Zotta E
Clin Kidney J; 2019 Feb; 12(1):53-60. PubMed ID: 30747154
[TBL] [Abstract][Full Text] [Related]
8. Creatinine- vs. cystatin C-based equations compared with 99mTcDTPA scintigraphy to assess glomerular filtration rate in chronic kidney disease.
Trimarchi H; Muryan A; Martino D; Toscano A; Iriarte R; Campolo-Girard V; Forrester M; Pomeranz V; Fitzsimons C; Lombi F; Young P; Raña MS; Alonso M
J Nephrol; 2012; 25(6):1003-15. PubMed ID: 22322818
[TBL] [Abstract][Full Text] [Related]
9. Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Costales-Collaguazo C; Stern A; Paulero M; Rengel T; Valiño-Rivas L; Forrester M; Lombi F; Pomeranz V; Iriarte R; Muryan A; Ortiz A; Sanchez-Niño MD; Zotta E
Int J Nephrol; 2017; 2017():1287289. PubMed ID: 28523190
[No Abstract] [Full Text] [Related]
10. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
11. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
[TBL] [Abstract][Full Text] [Related]
12. Post-partum podocyturia following pre-eclamptic pregnancy.
Furuta I; Zhai T; Umazume T; Ishikawa S; Hosokawa A; Kojima T; Chiba K; Yamada T; Morikawa M; Minakami H
J Obstet Gynaecol Res; 2017 Jun; 43(6):1008-1013. PubMed ID: 28621045
[TBL] [Abstract][Full Text] [Related]
13. Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.
Petrica L; Vlad M; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Popescu R; Gluhovschi C; Matusz P; Velciov S; Bob F; Ursoniu S; Vlad D
J Diabetes Complications; 2017 Sep; 31(9):1444-1450. PubMed ID: 28161386
[TBL] [Abstract][Full Text] [Related]
14. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?
Politei J; Alberton V; Amoreo O; Antongiovanni N; Arán MN; Barán M; Cabrera G; Di Pietrantonio S; Durand C; Fainboim A; Frabasil J; Pizarro FG; Iotti R; Liern M; Perretta F; Ripeau D; Toniolo F; Trimarchi H; Rivas DV; Wallace E; Schenone AB
Pediatr Nephrol; 2018 Nov; 33(11):2095-2101. PubMed ID: 29987457
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Beta 2-Microglobulin, Cystatin C, and Lipocalin-2 as Renal Biomarkers for Patients with Fabry Disease.
Braga MC; Fonseca FLA; Marins MM; Gomes CP; Bacci MR; Martins AM; D'Almeida V
Nephron; 2019; 143(4):217-227. PubMed ID: 31216546
[TBL] [Abstract][Full Text] [Related]
16. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
17. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
18. Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients.
Martineau T; Boutin M; Côté AM; Maranda B; Bichet DG; Auray-Blais C
Clin Chim Acta; 2019 Aug; 495():67-75. PubMed ID: 30898510
[TBL] [Abstract][Full Text] [Related]
19. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
20. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
